Skip to content
value.today

Comanche Biopharma Corp.

🇺🇸 Concord, Massachusetts, USAPharmaceuticalsFounded 2020

Formerly Comanche Corp.

Total raised
$74 M
2 rounds on record
Latest round
$38 M
Dec 2023
First round on record
Jun 2021
Today
Private
No later event on record

Funding rounds

2 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Comanche Biopharma Corp.
MonthRaisedRaiseSizeInvestorsSoldFiling
Dec 2023$38 MNo. 2$10 to $50 million

Comanche Biopharma Corp.: Raise no. 2, Dec 2023

Investors in this round

7 investors had bought by the notice of Jan 17, 2024: 7 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$38 M of $75 M offered; $38 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Allison Scott August · Executive Officer
  • Michael Scott Young · Executive Officer
  • Paul Scott Antinori · Executive Officer
  • Thomas Scott Johnson · Executive Officer, Director
  • Allyson Scott Felix · Director
  • Ann Scott Taylor · Director
  • Brendan Scott Bulik-Sullivan · Director
  • David Scott Grayzel · Director
  • Ketan Scott Patel · Director
  • Muzammil Scott Mansuri · Director
  • Scott Scott Gottlieb · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Thomas Scott Johnson, Chief Executive Officer. Source: SEC Form D, newest notice filed Jan 17, 2024. Read the notice at the SEC.

equitySEC
Jun 2021$36 MNo. 1$10 to $50 million

Comanche Biopharma Corp.: Raise no. 1, Jun 2021

Investors in this round

7 investors had bought by the notice of May 12, 2023: 7 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$36 M of $36 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
more than a year
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Allison Scott August · Executive Officer
  • Michael Scott Young · Executive Officer
  • Paul Scott Antinori · Executive Officer
  • Thomas Scott Johnson · Executive Officer, Director
  • Allyson Scott Felix · Director
  • Ann Scott Taylor · Director
  • Arthur Scott Levin · Director
  • Brendan Scott Bulik-Sullivan · Director
  • Clive Scott Meanwell · Director
  • Ketan Scott Patel · Director
  • Muzammil Scott Mansuri · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by T. Scott Johnson, Chief Executive Officer. Source: SEC Form D, newest notice filed May 12, 2023. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Comanche Biopharma Corp. chose not to state its revenue in its newest notice of a funding round (Jan 2024).

    SEC Form D · Jan 2024

  • The industry group it chose in its notices: Pharmaceuticals.

    SEC Form D · Jan 2024

That is all the official record says: Comanche Biopharma Corp. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of Comanche Biopharma Corp. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 2 rounds above had up to 7 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Comanche Biopharma Corp.
NameRoleNamed in
Allison Scott AugustExecutive officerJan 2024
Michael Scott YoungExecutive officerJan 2024
Paul Scott AntinoriExecutive officerJan 2024
Thomas Scott JohnsonExecutive officerJan 2024
Allyson Scott FelixDirectorJan 2024
Ann Scott TaylorDirectorJan 2024
Brendan Scott Bulik-SullivanDirectorJan 2024
David Scott GrayzelDirectorJan 2024
Ketan Scott PatelDirectorJan 2024
Muzammil Scott MansuriDirectorJan 2024
Scott Scott GottliebDirectorJan 2024
Thomas Scott JohnsonDirectorJan 2024
Arthur Scott LevinDirectorMay 2023
Clive Scott MeanwellDirectorMay 2023